CYP2D6 is of great importance for the metabolism of clinically used drugs and about 20–
25% of those are metabolised by this enzyme. In addition, the enzyme utilises …

CYP2D6 has received intense attention since the beginning of the pharmacogenetic era in
the 1970s. This is because of its involvement in the metabolism of more than 25% of the …

In this review we highlight the information available on the genetic polymorphism of
cytochrome P4502D6 expression in man. An absent function of this enzyme is observed in 7 …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Interindividual differences in the pharmacokinetics of a number of drugs are often due to
hereditary polymorphisms of drug‐metabolizing enzymes. Most important is cytochrome …

The cytochrome p450 enzyme, CYP2D6, metabolises approximately 20% of marketed
drugs. CYP2D6 multiple variants are associated with altered enzyme activities. Genotyping …

Abstract Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 25% of clinically
used drugs. Genetic polymorphisms cause substantial variation in CYP2D6 activity and …

Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of~
20% of commonly used drugs across a broad spectrum of medical disciplines including …

Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse
effects of drug therapies. The majority of hepatically cleared drugs are metabolized by …

Polymorphisms in the cytochrome P450 2D6 (CYP2D6) gene are a major cause of
pharmacokinetic variability in human. Although the poor metabolizer phenotype is known to …